Harnessing cytokines and chemokines for cancer therapy

DJ Propper, FR Balkwill - Nature reviews Clinical oncology, 2022 - nature.com
During the past 40 years, cytokines and cytokine receptors have been extensively
investigated as either cancer targets or cancer treatments. A strong preclinical rationale …

Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy

Y Lu, YT Chan, HY Tan, S Li, N Wang, Y Feng - Molecular cancer, 2020 - Springer
Epigenetics is dynamic and heritable modifications to the genome that occur independently
of DNA sequence. It requires interactions cohesively with various enzymes and other …

The roles of histone deacetylases and their inhibitors in cancer therapy

G Li, Y Tian, WG Zhu - Frontiers in cell and developmental biology, 2020 - frontiersin.org
Genetic mutations and abnormal gene regulation are key mechanisms underlying
tumorigenesis. Nucleosomes, which consist of DNA wrapped around histone cores …

Cutaneous T cell lymphoma

R Dummer, MH Vermeer, JJ Scarisbrick… - Nature Reviews …, 2021 - nature.com
Primary cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of lymphomas
that present in the skin with no evidence of extracutaneous disease at the time of diagnosis …

Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer

Z Zeng, M Fu, Y Hu, Y Wei, X Wei, M Luo - Molecular Cancer, 2023 - Springer
Cancer stem cells (CSCs), initially identified in leukemia in 1994, constitute a distinct subset
of tumor cells characterized by surface markers such as CD133, CD44, and ALDH. Their …

The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives

J Majidpoor, K Mortezaee - Clinical Immunology, 2021 - Elsevier
Colorectal cancer (CRC), and breast, ovarian, pancreatic and prostate cancers are generally
considered as low immune-reactive cancers that represent either limited infiltration of …

How chemokines organize the tumour microenvironment

TR Mempel, JK Lill, LM Altenburger - Nature Reviews Cancer, 2024 - nature.com
For our immune system to contain or eliminate malignant solid tumours, both myeloid and
lymphoid haematopoietic cells must not only extravasate from the bloodstream into the …

Targeting the CCL2–CCR2 axis for atheroprotection

MK Georgakis, J Bernhagen, LH Heitman… - European heart …, 2022 - academic.oup.com
Decades of research have established atherosclerosis as an inflammatory disease. Only
recently though, clinical trials provided proof-of-concept evidence for the efficacy of anti …

Fc-engineering for modulated effector functions—improving antibodies for cancer treatment

R Liu, RJ Oldham, E Teal, SA Beers, MS Cragg - Antibodies, 2020 - mdpi.com
The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage
innate immune effectors through interactions mediated by their fragment crystallizable (Fc) …

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

D Phillips, M Matusiak, BR Gutierrez, SS Bhate… - Nature …, 2021 - nature.com
Cutaneous T cell lymphomas (CTCL) are rare but aggressive cancers without effective
treatments. While a subset of patients derive benefit from PD-1 blockade, there is a critically …